Ocata Therapeutics, Inc.
http://www.ocata.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ocata Therapeutics, Inc.
New Daiichi Structure Strengthens Oncology Focus
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
Astellas Targets ALS In Expansion Of Cytokinetics Alliance
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
Chugai Makes Regenerative Meds Move In Attractive Japan Environment
Chugai is taking concrete steps into the burgeoning regenerative medicine sector in Japan through a new clinical and commercial alliance with a domestic venture for a therapy for knee cartilage disorders.
Company Information
- Other Names / Subsidiaries
-
- Advanced Cell Technology, Inc.
- Mytogen, Inc.